Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType DefinitionDescription dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
20370-3 Velocity-time integral.XXX Len Circulatory system.XXX Pt Qn US.doppler   ACTIVE Velocity-time integral.XXX by US.doppler   MIN DefinitionDescription                   CARD.US   20370-3   US.doppler     Observation       0 VTI.XXX DOP           CARD.US; Cardio; Cardiology; Circ; Circ sys; DOP; DUPLEX; Echography; Heart Disease; Length; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Sonogram; Sonograph; Sonography; Spec; To be specified in another part of the message; ULS; Ultrasound; Unspecified; Vel; VTI; VTI.XXX 2.4 1.0m                       0
20371-1 Velocity-time integral.XXX/Velocity-time integral 2.XXX LenRto Circulatory system.XXX Pt Qn US.doppler   ACTIVE Velocity-time integral.XXX/Velocity-time integral 2 by US.doppler   MAJ DefinitionDescription     index;ratio             CARD.US   20371-1   US.doppler     Observation       0 VTI.XXX/VTI 2 DOP           CARD.US; Cardio; Cardiology; Circ; Circ sys; DOP; DUPLEX; Echography; Heart Disease; II; Length Ratio; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Sonogram; Sonograph; Sonography; Spec; To be specified in another part of the message; ULS; Ultrasound; Unspecified; Vel; VTI; VTI 2; VTI 2.XXX; VTI.XXX 2.67 1.0m               {index};{ratio}     Release 2.67: PROPERTY: Updated for accuracy. 0
20372-9 Velocity-time integral 2.XXX Len Circulatory system.XXX Pt Qn US.doppler   ACTIVE Velocity-time integral 2 XXX by US.doppler   MIN DefinitionDescription                   CARD.US   20372-9   US.doppler     Observation       0 VTI 2.XXX DOP           CARD.US; Cardio; Cardiology; Circ; Circ sys; DOP; DUPLEX; Echography; Heart Disease; II; Length; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Sonogram; Sonograph; Sonography; Spec; To be specified in another part of the message; ULS; Ultrasound; Unspecified; Vel; VTI 2.XXX 2.4 1.0m                       0
20373-7 Amikacin Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Amikacin [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20373-7   Method for Slow-growing mycobacteria     Observation       0 Amikacin Islt SlowMyco           AFB; Amikin; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.73 1.0m                       0
20374-5 Ampicillin+Sulbactam Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Ampicillin+Sulbactam [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20374-5   Method for Slow-growing mycobacteria     Observation       0 Ampicillin+Sulbac Islt SlowMyco           AFB; Amcil; Amicil; Amp; Ampicilloyl; ANTIBIOTIC SUSCEPTIBILITIES; AST; c203; c5; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Omnipen; Penbritin; Point in time; Polycillin; Random; SlowMyco; Sulb; Sulbact; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis; Unasyn 2.26 1.0m                       0
20375-2 Clarithromycin Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Clarithromycin [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20375-2   Method for Slow-growing mycobacteria     Both       0 Clarithro Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Biaxin; Claripen; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Klacid; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.73 1.0m                       0
20376-0 Clofazimine Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Clofazimine [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20376-0   Method for Slow-growing mycobacteria     Observation       0 Clofazamine Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Clofazamine; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20377-8 Ciprofloxacin Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Ciprofloxacin [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20377-8   Method for Slow-growing mycobacteria     Observation       0 Ciprofloxacin Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c250; c307; C81; Ciloxan; Cipro; Ciprofloxacn; Ciprofloxin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.73 1.0m                       0
20378-6 Ceftizoxime Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Ceftizoxime [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20378-6   Method for Slow-growing mycobacteria     Observation       0 Ceftizoxime Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefizox; Ceftrix; Eposelin; Eposerin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20379-4 Doxycycline Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Doxycycline [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20379-4   Method for Slow-growing mycobacteria     Observation       0 Doxycycline Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c206; c216; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis; Vibramycin 2.26 1.0m                       0
2038-8 Carcinoembryonic Ag MCnc Semen Pt Qn     ACTIVE Carcinoembryonic Ag [Mass/volume] in Semen   MIN DefinitionDescription     ng/mL             CHEM   2038-8         Both       0 CEA Smn-mCnc       Y   Antigen; Antigens; CEA; Chemistry; Ejaculate; Genitourinary; GU; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sem; Seminal fluid; Smn; SMPLS; Tumor marker; URO; Urology 2.42 1               ng/mL       0
20380-2 Erythromycin Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Erythromycin [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20380-2   Method for Slow-growing mycobacteria     Observation       0 Erythromycin Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c212; EES; Erygel; Erythromycn; ID; Ilosone; Ilotycin; Iltycin; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20381-0 Ethambutol Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Ethambutol [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20381-0   Method for Slow-growing mycobacteria     Observation       0 Ethambutol Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Etambol; Ethamb; ID; Inagen; Infectious Disease; InfectiousDisease; Islt; Isol; Myambutol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Mycobutol; Olbutam; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20382-8 Ethionamide Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Ethionamide [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20382-8   Method for Slow-growing mycobacteria     Observation       0 Ethionamide Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Trecator; Tuberculosis 2.26 1.0m                       0
20383-6 Isoniazid Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Isoniazid [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20383-6   Method for Slow-growing mycobacteria     Observation       0 Isoniazid Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Hyzyd; ID; Infectious Disease; InfectiousDisease; INH; Islt; Isol; Isoniaz; Isoniazide; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Nudrazod; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20384-4 Ofloxacin Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Ofloxacin [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20384-4   Method for Slow-growing mycobacteria     Observation       0 Ofloxacin Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c409; Floxin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20385-1 rifAMPin Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE rifAMPin [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20385-1   Method for Slow-growing mycobacteria     Observation       0 rifAMPin Islt SlowMyco           AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c301; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; RIF; Rifadin; Rifampicin; Rimactane; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20386-9 Rifabutin Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Rifabutin [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20386-9   Method for Slow-growing mycobacteria     Observation       0 Rifabutin Islt SlowMyco           AFB; Ansamycin; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Mycobutin; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 1.0m                       0
20387-7 Trimethoprim+Sulfamethoxazole Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria   ACTIVE Trimethoprim+Sulfamethoxazole [Susceptibility] by Method for Slow-growing mycobacteria   MIN DefinitionDescription                   ABXBACT   20387-7   Method for Slow-growing mycobacteria     Observation       0 TMP SMX Islt SlowMyco           Acetylsulfamethoxazole; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Bactrim; c202; c203; c223; c242; C61; C62; Cotrim; Cotrimoxazole; Co-trimoxazole; Gantanol; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Polytrim; Primsol; Proloprim; Random; Septra; SlowMyco; SMX; SMX-TMP; Sulfa; Sulfamethox; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; SXT; TB; TMP; TMP SMX; TMP-SMX; Trimeth; Trimpex; Tuberculosis 2.73 1.0m                       0
20388-5 Nitrofurazone Susc Isolate Pt OrdQn     ACTIVE Nitrofurazone [Susceptibility]   MIN DefinitionDescription     mm             ABXBACT   20388-5         Observation       0 Nitrofurazone Susc Islt           ANTIBIOTIC SUSCEPTIBILITIES; AST; Furacilin; Furacin; Furacin.topical; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Nitrofural; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Vet; Veterinary 2.5 1.0m               mm     Term was named using the trade name, Furacin. Updated component with the generic name, nitrofural, based on LOINC model for naming analytes. 0
20389-3 Mupirocin Susc Isolate Pt OrdQn     ACTIVE Mupirocin [Susceptibility]   MIN DefinitionDescription     mm             ABXBACT   20389-3         Observation       0 Mupirocin Susc Islt           ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.21 1.0m               mm       0
2039-6 Carcinoembryonic Ag MCnc Ser/Plas Pt Qn     ACTIVE Carcinoembryonic Ag [Mass/volume] in Serum or Plasma   MIN DefinitionDescription     ug/L;ng/mL             CHEM   2039-6         Both       0 CEA SerPl-mCnc       Y   Antigen; Antigens; CEA; Chemistry; Level; Mass concentration; Oncology; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker; UniversalLabOrders 2.73 1               ng/mL       211
20390-1 Silver sulfADIAZINE Susc Isolate Pt OrdQn     ACTIVE Silver sulfADIAZINE [Susceptibility]   MIN DefinitionDescription     mm             ABXBACT   20390-1         Observation       0 Silvadene Susc Islt           Ag; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microsulfon; Point in time; Random; Silv; Silvadene; Silvadine.topical; Silverex; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.73 1.0m               mm     Changed Component name from 'Silvadine.topical' to the generic name, silver sulfadiazine. 0
20391-9 Mafenide Susc Isolate Pt OrdQn     ACTIVE Mafenide [Susceptibility]   MIN DefinitionDescription     mm             ABXBACT   20391-9         Observation       0 Mafenide Susc Islt           ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sulfamylon.topical; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty 2.21 1.0m               mm       0
20392-7 Sample icteric PrThr Ser/Plas Pt Ord     ACTIVE Sample icteric [Presence] of Serum or Plasma Qualitative   MIN DefinitionDescription                   SPEC   20392-7         Observation       0 Sample Icteric SerPl Ql           Icterus; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SPEC; SR 2.73 1.0m                     The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
104,672 results found